evidencegaps
Findings

What do systematic reviews say?

Refine by population, intervention, comparison or outcome
More filters
Evidence found and GRADE certainty

4,756 questions · 13,493 findings · 1,305 reviews · Headline outcomes only

Sort:Best matchNewestHighest certaintyDownload CSV
No studies found 2,594 · 19.2%GRADE not reported 728 · 5.4%Very low 2,868 · 21.3%Low 3,777 · 28%Moderate 2,620 · 19.4%High 906 · 6.7%

Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.

Reslizumab intravenous (IV) vs placebo

Serious adverse events · people with asthma

Reslizumab intravenous (IV) showed no clear difference in serious adverse events compared with placebo (high certainty).

1 finding from 1 review

Reslizumab intravenous (IV) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab intravenous (IV) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Rate of exacerbations requiring emergency department treatment or admission · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in rate of exacerbations requiring emergency department treatment or… compared with placebo (high certainty).

1 finding from 1 review

Reslizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Reslizumab subcutaneous (SC) showed no clear difference in clinically significant adverse events leading to discontinuation compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Rate of clinically significant exacerbations requiring systemic corticosteroids · people with asthma

Benralizumab subcutaneous (SC) leads to lower rate of clinically significant exacerbations requiring systemic… compared with placebo (high certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Rate of exacerbations requiring emergency department treatment or admission · people with asthma

Benralizumab subcutaneous (SC) probably leads to lower rate of exacerbations requiring emergency department treatment or… compared with placebo (moderate certainty).

1 finding from 1 review

Benralizumab subcutaneous (SC) vs placebo

Clinically significant adverse events leading to discontinuation · people with asthma

Benralizumab subcutaneous (SC) leads to higher clinically significant adverse events leading to discontinuation compared with placebo (high certainty).

1 finding from 1 review